
Bausch + Lomb Shares Rise After Q2 Revenue Beat, Raised Full-Year Guidance
The eye health company's stock is trading higher after it reported second-quarter revenue that surpassed analyst expectations and lifted its full-year 2026 sales forecast, citing significant improvements in profitability.







